

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number
WO 03/080074 A1

- (51) International Patent Classification⁷: **A61K 31/7028**, 31/485
- (21) International Application Number: PCT/US03/08448
- (22) International Filing Date: 19 March 2003 (19.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/365,454 19 March 2002 (19.03.2002) US
- (63) Related by continuation (CON) or continuation-in-part (CIP) to earlier application:
US 60/365,454 (CON)
Filed on 19 March 2002 (19.03.2002)
- (71) Applicant and
(72) Inventor: **HOLICK, Michael** [US/US]; 31 Bishop Lane, Sudbury, MA 01776 (US).
- (72) Inventor; and
(75) Inventor/Applicant (for US only): **RAMANATHAN, Halasya** [—/US]; Fitchburg, MA (US).
- (74) Agent: **CLARK, Paul, T.**; Clark & Elbing LLP, 101 Federal Street, Boston, MA 02110 (US).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 03/080074 A1

(54) Title: GLYCOSIDE AND ORTHOESTER GLYCOSIDE DERIVATIVES OF APOMORPHINE, ANALOGS, AND USES THEREOF

(57) Abstract: Disclosed are glycoside and orthoester glycoside derivatives of apomorphine and analogs thereof to treat conditions and diseases such as erectile dysfunction.

dysfunction. Such side effects include nausea, hypertension, flushing and diaphoresis. The patents also teach that apomorphine has poor oral bioavailability. Also disclosed is the oral administration of apomorphine and an antiemetic agent to substantially reduce nausea.

5 U.S. Pat. No. 5,888,534 discloses the controlled release of apomorphine by sublingual or buccal administration for the treatment of psychogenic impotence and Parkinson's disease.

U.S. Pat. No. 5,939,094 discloses dosage forms for the transdermal administration of apomorphine for the treatment of Parkinson's disease.

10 U.S. Pat. No. 5,994,363 discloses the treatment of Parkinson's disease and psychogenic erectile dysfunction and the amelioration of apomorphine adverse effects such as nausea, vomiting, yawning, and cardiovascular effects, by a dose escalating method of acclimatization.

U.S. Pat. No. 5,945,117 discloses the treatment of female sexual
15 dysfunction, without substantial undesirable side effects, by sublingual administration of apomorphine dosage forms. Administration of apomorphine increases nerve stimulated clitoral intracavernosal blood flow and vaginal wall blood flow for enhanced clitoral erection and vaginal engorgement in a female. A plasma concentration of apomorphine of no more than about 5.5 nanograms
20 per milliliter is preferably maintained.

U.S. Pat. No. 6,001,845 discloses a method of treating sexual
dysfunction comprising administering a therapeutically effective amount of a
combination of phentolamine or a salt, solvate, hydrate, or crystalline
polymorph thereof and apomorphine or a salt, solvate or hydrate thereof. The
25 two drugs may be administered either substantially concurrently in separate dosage forms or combined in a single unit dosage form. See also U.S. Pat. No. 6,011,043.

U.S. Pat. No. 6,087,362 discloses a method for the treatment of sexual
dysfunction in human patients by administering orally apomorphine and
30 sildenafil. According to the '362 patent, the combination optimizes the

efficacy of each drug and minimizes the undesirable side effects associated with the individual drugs. The drugs may be coadministered in a combination dosage form or administered sequentially in separate dosage forms prior to sexual activity. Also according to the '362 patent, antiemetic agents such as

5 antidopaminergic agents (e.g. benzamides such as metaclopramide, trimethobenzamide, benzoquinamid), phenothiazines (e.g. chlorpromazine, prochlorperazine, pipamazine, thienylperazine, oxypendyl hydrochloride, promazine, triflupromazine, propiomazine, acepromazine, acetophenazine, butaperazine, carpherazine, fluphenazine, perphenazine, thiopropazate,

10 trifluoperazine, mesoridazine, peperacetazine, thioridazine, pepotiazine, pepotiazine palmitate, chlorprothixine, doxepin, loxapin, triflupromazine, methdilazine, trimeprazine, and methotrimeprazine), serotonin (5-hydroxytryptamine or 5-HT) antagonists (e.g. domperidone and ondansetron), histamine antagonists (e.g. buclizine hydrochloride, cyclizine hydrochloride and dimenhydrinate), parasympathetic depressants (e.g. scopolamine), other

15 antiemetics (e.g. metopimazine, trimethobenzamide, benzoquinamine hydrochloride and diphenidol hydrochloride), and piperazines (e.g. meclizine and chlorcyclizine) may be coadministered.

U.S. Pat. No. 6,136,818 discloses administering a combination of

20 phentolamine and apomorphine for the treatment of human sexual function and dysfunction.

U.S. Pat. No. 6,266,560 discloses a method for enhancing erectile function by applying an electric pulse to the penis and substantially contemporaneously applying a vasoactive or androgenic composition thereto.

25 Examples of vasoactive compounds include apomorphine.

U.S. Pat. No. 6,291,471 discloses a method of treating male organic erectile dysfunction having a vasculogenic origin by orally administering an effective amount of apomorphine or a salt thereof.

U.S. Pat. No. 6,316,027 discloses fast dissolving dosage forms comprising dopamine agonists such as apomorphine, water, gelatin and other ingredients for the treatment of Parkinson's disease.

5

SUMMARY OF THE INVENTION

The present invention relates to a pro-drug approach to apomorphine therapy that provides better bioavailability, less emetic action and allows oral administration. The pro-drug is in the form of glycosides and orthoester glycosides of apomorphine and analogs thereof. The catechol moiety in apomorphine may be glycosylated cleanly to give one major isomer. When administered, glycosidase enzymes in the biological medium of human body cleave the glycoside/orthoester glycoside, liberating the free drug. Thus the free drug is bioavailable in a controlled fashion as determined by the rate of deglycosylation.

15

Apomorphine is a dopamine receptor agonist that acts on the central nervous system. Once absorbed and transported into the brain, apomorphine initiates a chain of reactions that result in increased blood flow to the male genital organs and an erection. Thus, apomorphine and its glycosides/ortho ester glycosides derivatives can be used to treat sexual dysfunctions,

20

Parkinson's disease and other conditions treatable with apomorphine.

25


In a first aspect, the present invention provides a composition for the treatment of a condition treatable by the administration of apomorphine or an analog thereof, characterized in that the apomorphine or analog thereof is a derivative in the form of a glycoside or orthoester glycoside, derivative or salt or ester of the derivative.

The present invention also relates to compounds of the Formula (I):



or a salt or ester thereof;

wherein Apo is an apomorphine residue or analog thereof, n is 1 or 2, and R₁ is
 5 a straight or branched chain glycosidic moiety containing 1-20 glycosidic units,
 or R₁ is an orthoester glycoside moiety of the Formula (II):




wherein A represents a glycofuranosyl or glycopyranosyl ring;

R₂ is hydrogen or alkyl;

10 R₃ is hydrogen or a straight or branched chain glycosidic moiety
 containing 1-20 glycosidic units; or

when n is 2, both R₁ groups form a ketal or acetal having the

Formula (III):




15 wherein X is a straight or branched chain alkylene group;

R₄ and R₅ are independently hydrogen or an alkyl group; and


R₆ is a straight or branched chain glycosidic moiety containing 1-20 glycosidic
 units or an orthoester glycoside as defined above.

In a preferred embodiment, the compound has one of Formulae (IV), (V), or (VI) or (VII):




5

IV




V



10

VI



VII

or a salt, or ester thereof, wherein R₁ is defined above.


The invention also relates to a method for the treatment or amelioration
5 of senile dementia and dementia associated with neurodegenerative diseases
such as Alzheimer's disease and other disorders involving memory loss and/or
dementia (including AIDS dementia); disorders of attention and focus (such as
attention deficit disorder); disorders of extrapyramidal motor function such as
Parkinson's disease, Huntington's disease, Gilles de la Tourette syndrome and
10 tardive dyskinesia; mood and emotional disorders such as depression, panic,
anxiety and psychosis treatment or amelioration of erectile dysfunction or
female sexual dysfunction, comprising administering to an animal in need
thereof, an effective amount of a compound having the Formulae (I), (IV), (V),
(VI) or (VII), or a pharmaceutically acceptable salt or ester thereof.

15 The invention also relates to a method of preparing a compound of
Formulae (I), (IV), (V) and (VI) which comprises reacting a protected α -
bromoglycoside or orthoester glycoside with apomorphine or analog thereof in
the presence of a base and cleaving the protecting groups. The desired
compound may be isolated from a mixture of products either before or after the
20 protecting groups are cleaved.

In a further embodiment, apomorphine or analog thereof may be
glycosylated with the glycosylation donor 1-trichloroacetamidoyl-2,3,4,6-tetra-
O-acyl-glycopyranoside in an aprotic solvent under an inert atmosphere. A


Lewis acid such as boron trifluoride etherate is added, the reaction stirred and the product isolated. Cleavage of the acyl protecting groups gives the apomorphine glycoside.

In another embodiment, the catechol moiety of apomorphine is
 5 ketalized with an aldehyde or ketone having the Formula (VIII):




wherein X, R₄ and R₅ are defined above and the hydroxy groups on R₆ are protected. Removal of the protecting groups gives a compound of Formula I.

By "apomorphine analog" is meant a dopamine receptor agonist of
 10 formulas IX or X:



IX



X

wherein R₇ is hydrogen, alkyl, halogen substituted alkyl, hydroxyl substituted
 15 alkyl, aryl substituted alkyl, acyl substituted alkyl, acyl, or aryl; R₈ and R₉ are
 each independently selected from hydrogen, hydroxyl, alkyl, sulfhydryl,
 halogen, -O-alkyl, and -O-acyl, provided that at least one of R₈ and R₉ is a
 hydroxy group; and each methine and methylene proton of formulas IX and X
 are optionally substituted by halogen, nitro, -NH₂, secondary amino, tertiary
 20 amino, quaternary amino, -S-alkyl, -S-acyl, sulfhydryl, hydroxyl, alkyl, -O-
 alkyl, -O-acyl, halogen substituted alkyl, hydroxyl substituted alkyl, aryl
 substituted alkyl, and acyl substituted alkyl. Furthermore, apomorphine
 analogs include those compounds disclosed in U.S. Patent Nos. 4,120,964;

4,353,912; 4,543,256; and 6,313,134, hereby incorporated by reference.

Exemplary apomorphine analogs include (R)-N-n-propylnorapomorphine, (R)-N-methyl-10-hydroxyhexahydroaporphine, (R)-11-hydroxy-10-methyl aporphine, and (R)-11-hydroxy-N-n-propylnoraporphine.

5

DETAILED DESCRIPTION OF THE INVENTION

Where the derivative is a glycoside, then it is preferred that it contain 1-20 glycosidic units.

10 It is preferred that compounds of the present invention have less than 10 and, more preferably, 3 or less glycosidic units. Specific examples are those containing 1 or 2 glycosidic units in the glycoside moiety, such as glucose and sucrose, with one being most preferred.

By glycosidic units are meant glycopyranosyl or glycofuranosyl, as well
15 as their sulfates, amino sugar and/or deoxy derivatives. The configuration of each unit may be D or L, although D is generally preferred. The moieties may be homopolymers, random or alternating polymers, or block copolymers of these monomers.

The glycosidic units have free hydroxy groups, or the hydroxy groups
20 may be acylated, e.g. with a group $R_4-(C=O)-$, wherein R_4 is hydrogen, C_{1-6} alkyl, C_{6-10} substituted or unsubstituted aryl or C_{7-16} aralkyl. Preferably, the acyl groups are acetyl or propionyl. Other preferred R_4 groups are phenyl, nitrophenyl, halophenyl, lower alkyl substituted phenyl, lower alkoxy substituted phenyl and the like or benzyl, lower alkoxy substituted benzyl and
25 the like.

The glycopyranose or glycofuranose ring or amino derivative thereof
may be fully or partially acylated or completely deacylated. The completely or partially acylated glycoside is useful as a defined intermediate for the synthesis
of the deacylated material. Useful protecting groups include, but are not
30 limited to, acetyl, benzoyl, nicotinoyl, benzyl, methyl and phenyl.

Among the possible glycopyranosyl structures are glucose, mannose, galactose, gulose, allose, altrose, idose, or talose. Among the furanosyl structures, the preferred ones are derived from fructose, ribose, arabinose or xylose. Among preferred diglycosides are sucrose, cellobiose, maltose, lactose, 5 trehalose, gentiobiose, and melibiose. Among the triglycosides, the preferred ones may be raffinose or gentianose.

Preferred aminosugar derivatives are N-acetyl-D-galactosamine, N-acetyl-D-glucosamine, N-acetyl-D-mannosamine, N-acetylneuraminic acid, D-glucosamine, D-lyxosylamine, D-galactosamine, chondroitin, and the like. 10 In addition, such active units as chondroitin sulfate and D-glucosamine sulfate may also be employed, as such sub-units independently have advantageous therapeutic osteopathic properties.

Where there are linked glycosidic units, i.e., there is a di or polyglycosidic moiety, the individual glycosidic rings may be bonded by 1-1, 15 1-2, 1-3, 1-4, 1-5 or 1-6 bonds, most preferably 1-2, 1-4 and 1-6. The linkages between individual glycosidic rings may be α or β .

Alkyl groups may be straight, branched or cyclic and may conveniently be a C₁₋₁₀ alkyl, including octyl, nonyl, decyl, diethylhexyl, and, more preferably, C₁₋₆, such as methyl, ethyl, propyl, butyl, methylpropyl, t-butyl, 20 pentyl, dimethylpropyl, hexyl, dimethylbutyl or ethylbutyl. Preferred alkyl groups contain 1 or 2 carbon atoms. Methyl and ethyl groups are particularly preferred, especially methyl.

Straight and branch chain alkylene groups include C₁₋₆ alkylene groups optionally substituted with one or more alkyl groups.

25 Aryl groups generally have 6 to 14 carbon atoms having a single ring (e.g., phenyl) or multiple condensed rings (e.g., naphthyl or anthryl). Preferred aryl groups are phenyl and naphthyl, preferably phenyl.

Especially preferred apomorphine derivatives include, without limitation, those with Formulae (IV)-(VII), wherein R₁ is a glucosyl moiety.

The compounds useful in the practice of the invention contain at least one glycoside or orthoester glycoside moiety connected to the 10- and/or 11-hydroxyl group of apomorphine or analog thereof.

The water soluble glycosidic derivatives of the aforementioned
5 apomorphine and analogs thereof may be obtained according to the general methods disclosed U.S. Pat. No. 4,410,515, the contents of which are fully incorporated by reference herein.

Salts of the compounds of the invention include any pharmaceutically acceptable salts include the acid addition salts with e.g. hydrogen chloride,
10 sulfuric acid, phosphoric acid, acetic acid, malic acid, carbonic acid and the like.

Esters of the compounds of the invention include esters of any free hydroxy groups on apomorphine and analogs thereof. Such esters include the group $R_4-(C=O)-$, wherein R_4 is as defined above.

15 The invention is related in particular to the synthesis of compounds of Formula (I). In one embodiment, apomorphine or analog thereof may be glycosylated with the glycosylation donor 1-trichloroacetamidoyl-2,3,4,6-tetra-O-acyl-glycopyranoside in an aprotic solvent under an inert atmosphere. Examples of such acyl groups include $R_4-(C=O)-$ defined herein above.
20 Especially preferred acyl groups are acetyl groups. Examples of aprotic solvents include dichlormethane, chloroform and the like. The reaction is stirred at ambient temperature and a Lewis acid such as boron trifluoride etherate is added, the reaction stirred and the product isolated. Isolation may be accomplished with any conventional method such as column
25 chromatography on silica gel. Cleavage of the acyl protecting groups gives the apomorphine glycoside. When the protecting groups are C_{2-6} alkanoyl, they may be removed by any known methods including treatment with alkali alkoxide in alcohol (e.g., sodium methoxide in methanol) or by treatment with a basic resin in alcohol (e.g., DOWEX 110-OH in methanol). In the case of

30

trialkylsilyl and aryldialkylsilyl protecting groups, they may be removed in the presence of fluoride (e.g., tetrabutylammonium fluoride). In the case of benzyl groups, they may be removed by hydrogenation.

In a second embodiment, a protected α -bromoglycoside or orthoester
5 glycoside is reacted with apomorphine or an analog thereof in the presence of a base and the protecting groups are cleaved. The desired compound may be isolated from a mixture of products either before or after the protecting groups are cleaved.

Examples of bases that can be used to form the desired linkage between
10 apomorphine or an analog thereof and a bromoglycoside or orthoester glycoside include cadmium carbonate, silver carbonate, silver silicate, barium carbonate, lanthanum carbonate or oxalate, ytterbium carbonate or oxalate, and uranium carbonate or oxalate. In some cases, the glycoside or orthoester glycoside incorporates protecting groups. Examples of protecting groups
15 include C₂₋₆ alkanoyl groups (e.g., the peracetate) and trialkylsilyl groups (e.g., t-butyl dimethylsilyl and triisopropylsilyl). The reaction is carried out in an aprotic solvent, such as benzene, toluene, tetrahydrofuran, xylenes, chlorobenzene, dichlorobenzenes and the like.

The reaction temperature is from about 80 to 120 °C. Preferably, the
20 reaction temperature is about 110 °C.

The reaction may be carried out for about 1 to 18 hours, preferably, about 4 hours or until TLC shows that the reaction is complete.

The thus formed apomorphine or analog thereof-glycoside or orthoester glycoside is then isolated and may be purified on a silica gel column. The
25 protecting groups can then be removed and the glycoside/orthoester glycoside can be isolated and purified.

Representative examples of diseases and conditions treatable by compounds of the present invention are as listed hereinabove, and include, but are not limited to, erectile dysfunction, female sexual dysfunction, senile
30 dementia and dementia associated with neurodegenerative diseases such as

Alzheimer's disease and other disorders involving memory loss and/or dementia (including AIDS dementia); disorders of attention and focus (such as attention deficit disorder); disorders of extrapyramidal motor function such as Parkinson's disease, Huntington's disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, panic, anxiety and psychosis.

Benign Prostatic Hyperplasia (BPH) has been associated with erectile dysfunction (ED). Apomorphine is known to be useful for treating for ED in patients with BPH. Thus, the compounds of the invention are useful for treating and ameliorating ED associated with BPH.

Coronary artery disease (CAD) is also associated with ED. Thus, the compounds of the invention are also useful for treating and ameliorating ED associated with CAD.

Particularly preferred routes of administration of the compounds of the present invention are per os, such as elixirs, tablets and capsules, as exemplified below.

More generally, the compounds of the present invention can be administered in any appropriate pharmaceutically acceptable carrier for oral administration, since the apomorphine and apomorphine analog glycoside/orthoester glycoside derivatives are biologically active upon oral administration. The compounds of the invention may also be administered in any appropriate pharmaceutical carrier for parenteral, intramuscular, transdermal, intranasal, buccal or inhalation administration. They can be administered by any means that treat or ameliorate erectile dysfunction, female sexual dysfunction, senile dementia and dementia associated with neurodegenerative diseases such as Alzheimer's disease and other disorders involving memory loss and/or dementia (including AIDS dementia); disorders of attention and focus (such as attention deficit disorder); disorders of extrapyramidal motor function such as Parkinson's disease, Huntington's

30

disease, Gilles de la Tourette syndrome and tardive dyskinesia; mood and emotional disorders such as depression, panic, anxiety and psychosis, ED associated with BPH and ED associated with CAD.

The compounds of the invention may also be administered by a dose
5 escalating method of acclimatization as described in U.S. Pat. No. 5,994,363 thereby ameliorating any apomorphine adverse effects.

The compounds of the invention may also be administered by applying
an electric pulse to the penis as described in U.S. Pat. No. 6,266,560 and
substantially contemporaneously applying a composition of the invention
10 thereto, thereby inducing an erection.

The dosage administered will depend on the age, health and weight of
the recipient, kind of concurrent treatment, if any, frequency of treatment and
the nature of the effect desired. An exemplary systemic daily dosage is about
0.1 mg to about 500 mg. Normally, from about 1.0 mg to 100 mg daily of the
15 glycoside/orthoester glycoside, in one or more dosages per day, is effective to
obtain the desired results. One of ordinary skill in the art can determine the
optimal dosages and concentrations of active compounds with only routine
experimentation.

The compounds can be employed in dosage forms such as tablets and
20 capsules for oral administration. Such dosage forms may comprise well know
pharmaceutically acceptable carriers and excipients. In a preferred
embodiment, the dosage forms comprise cyclodextran and/or other saccharides
and/or sugar alcohols. The compounds may also be formulated in a sterile
liquid for formulations such as solutions or suspensions for parenteral use. A
25 lipid vehicle can be used in parenteral administration. The compounds could
also be administered via topical patches, ointments, gels or other transdermal
applications. In such compositions, the active ingredient will ordinarily be
present in an amount of at least 0.001 % by weight based on the total weight of
the composition, and not more than 50 % by weight. An inert pharmaceutically
30 acceptable carrier is preferable such as 95% ethanol, vegetable oils, propylene

glycols, saline buffers, sesame oil, etc. Methods well known in the art for making formulations are found, for example, in "Remington: The Science and Practice of Pharmacy" (20th ed., ed. A.R. Gennaro AR., 2000, Lippincott Williams & Wilkins).

5 The compounds may also be employed in fast dissolving dosage forms, as described in U.S. Pat. No. 6,316,027, hereby incorporated by reference, comprising the compounds of the invention, water, gelatin and other ingredients.

 Topical formulations for transdermal, intranasal or inhalation
10 administration may be prepared according to methods well known in the art. For topical administration, the compounds may be applied in any of the conventional pharmaceutical forms. For example, the compounds may be administered as part of a cream, lotion, aerosol, ointment, powder, drops or transdermal patch. Ointments and creams may, for example, be formulated
15 with an aqueous or oily base with the addition of suitable thickening and/or gelling agents. Such bases may include water and/or an oil such as liquid paraffin or a vegetable oil such as peanut oil or castor oil. Thickening agents which may be used include soft paraffin, aluminum stearate, cetostearyl alcohol, polyethylene glycols, wool-fat, hydrogenated lanolin, beeswax and the
20 like.

 Lotions may be formulated with an aqueous or oily base and will in general also include one or more of a stabilizing agent, thickening agent, dispersing agent, suspending agent, thickening agent, coloring agent, perfume and the like.

25 Powders may comprise any suitable powder base including talc, lactose, starch and the like. Drops may comprise an aqueous or non-aqueous base together with one or more dispersing agents, suspending agents, solubilizing agents and the like.

The compositions may further comprise one or more preservatives including bacteriostatic agents including methyl hydroxybenzoate, propyl hydroxybenzoate, chlorocresol, benzalkonium chloride and the like.

The topical compositions comprise from about 0.0001% to 5% by weight, preferably, 0.001 to 0.5% by weight, more preferably, 0.01 to 0.25% by weight of the active compounds.


The compounds may be administered together with therapeutically effective amounts of other compounds such as yohimbine, antiemetic agents such as antidopaminergic agents (e.g. benzamides such as metaclopramide, trimethobenzamide, benzoquinamid), phenothiazines (e.g. chlorpromazine, prochlorperazine, pipamazine, thienylperazine, oxypendyl hydrochloride, promazine, triflupromazine, propiomazine, acepromazine, acetophenazine, butaperazine, carpherazine, fluphenazine, perphenazine, thiopropazate, trifluoperazine, mesoridazine, peperacetazine, thioridazine, pepotiazine, pepotiazine palmitate, chlorprothixine, doxepin, loxapin, triflupromazine, methdilazine, trimeprazine, and methotrimeprazine), serotonin (5-hydroxytryptamine or 5-HT) antagonists (e.g. domperidone and odansetron), histamine antagonists (e.g. buclizine hydrochloride, cyclizine hydrochloride and dimenhydrinate), parasympathetic depressants (e.g. scopolamine), other antiemetics (e.g. metopimazine, trimethobenzamide, benzoquinamine hydrochloride and diphenidol hydrochloride), and piperazines (e.g. meclizine and chlorcyclizine). Such combinations optimize the efficacy of each drug and minimize the undesirable side effects associated with the individual drugs. The drugs may be coadministered in a combination dosage form or administered sequentially in separate dosage forms, e.g. prior to sexual activity.

In a preferred embodiment, the compounds of the invention are administered together with sildenafil, or a pharmaceutically acceptable salt or glycoronide (e.g. glucoronidea and galactoronides) thereof. Such glycoronides may be prepared by acylation of the sildenafil amide with, e.g. a hydroxy group protected active ester form of the glycoronide or with a protected

glycuronolactone (e.g. a protected glycuronolactone) as described in U.S. Pat. Nos. 5,977,326 and 4,774,230, each of which is hereby incorporated by reference. Cleavage of the protecting groups gives sildenafil glycoronide. The glucose transporters within the neuro cells may facilitate the uptake of the glycoronide conjugate before sildenafil is metabolized to inactive substances. The glycoronide conjugate releases the sildenafil by the action of amidases or glucosidases in a controlled fashion and also increases the biological stability of the sildenafil by increasing its half life.

The compounds of the invention may also be administered together with phentolamine and salts thereof (e.g. phentolamine mesylate), as well as glycosides and orthoester glycosides of phentolamine. Such glycosides and orthoester glycosides are prepared by derivatizing the hydroxy group of phentolamine with a glycoside or orthoester glycoside as described herein. In an alternative embodiment, a glycuronic ester, e.g., glycuronic acid ester of phentolamine may be prepared and administered.

The compounds of the invention may also be administered together with alprostadil, as well as glycosides, orthoester glycosides, glycuronides and amino sugar conjugates thereof. Alprostadil has the formula:



The glycosides and orthoester glycosides may be prepared by conjugation of protected α -bromoglycosides and orthoester glycosides with lower alkyl esters of alprostadil. Alternatively, alprostadil may be conjugated with 1-trichloroacetamidoyl-2,3,4,6-tetra-O-acyl-glycopyranoside. Saponification of the ester group and removal of the protecting groups on the sugar residue(s) gives the glycosides and orthoester glycosides of alprostadil. The amino sugar conjugates may be prepared by conjugation of the carboxylic

acid of alprostadil with a protected amino sugar such as glucosamine peracetate. In addition, one or both of the free hydroxyl groups may be derivatized with glycosides and orthoester glycosides as described herein. Glycoronides may be prepared by condensing the alkyl ester of alprostadil with
5 a protected glycuronolactone. See U.S. Pat. Nos. 5,977,326 and 4,908,927, or by an acid catalyzed conjugation reaction with a glucuronate ester according to U.S. Pat. No. 5,621,087, each of which is hereby incorporated by reference.

Alprostadil may be applied topically and, in females, it may be administered urethrally. Such glycosides, orthoester glycosides, and amino
10 sugar conjugates of alprostadil provide better permeation through the skin and better pharmacokinetic profiles compared to alprostadil.

The compounds of the invention are substantially pure. The phrase "substantially pure" encompasses compounds created by chemical synthesis and/or compounds substantially free of chemicals which may accompany the
15 compounds in the natural state, as evidenced by thin layer chromatography (TLC) or high performance liquid chromatography (HPLC).

Animals which may be treated according to the methods of the present invention include all animals which may benefit therefrom. Included in such animals are humans, although the invention is not intended to be so limited.

20 Having now generally described this invention, the same will be understood by reference to the following examples which are provided herein for purposes of illustration only and are not intended to be limiting unless otherwise specified.

25

EXAMPLE 1

Synthesis of R (-)-10- β -D-glucopyranosyl-, 11-hydroxyaporphine
(apomorphine glucoside)5 *Preparation of apomorphine:*

Apomorphine hydrochloride was purchased from Sigma/Aldrich and was used as such. 1-Trichloro acetamido glucose tetra acetate was made from glucose pentaacetate. Glucose pentaacetate and Boron trifluoride etherate was bought from Aldrich.

10 Conversion of 10,11-Dihydroxyaporphine hydrochloride to 10,11-dihydroxyaporphine (free base):

Apomorphine as free base is prone to oxidation rapidly and also it is light sensitive. By following the following method, apomorphine can be obtained as a pure white solid.

15 5 grams of apomorphine hydrochloride was suspended in sonicated argon purged water (500 mL) and a saturated sodium bicarbonate solution (100 mL) was added in one lot under argon. The sodium bicarbonate solution was prepared freshly, filtered and argon purged to avoid discoloring the product. The neutralized solution was stirred for 30 minutes and ether extracted (3 X
20 100 mL). The combined ether layer was washed with water (100 mL) once and dried with magnesium sulfate. Upon evaporation of ether under reduced pressure, apomorphine free base was obtained as colorless crystals quantitatively.

Proton NMR spectrum of apomorphine free base in CDCl_3 δ 8.2-7
25 (multiplets; Ar-H; 5 H), δ 3.2-2.4 (multiplets, 7-aliphatic-H) and δ 2.5 (singlet; N- CH_3 ; 3-H)

Preparation of 1-Hydroxy-2,3,4,6-tetra-O-acetyl-D-glucopyranoside:

Glucose penta-acetate (78g, 0.2mole) was dissolved in tetrahydrofuran (250ml, HPLC grade) and purged with argon. Benzyl amine (25.7g, 0.22mole) was added at room temperature. The mixture was stirred at room temperature
5 for 12 hours. Tetrahydrofuran was removed by rotary evaporator below 40 C. Dichloromethane (400mL) and ice cold dilute hydrochloric acid (1% solution in water, 500mL) were added to the above mixture and the aqueous layer was washed once with dichloromethane (100mL). Combined organic extracts were washed once with water and saturated sodium bicarbonate solution (100mL
10 each). The Organic layer was dried and evaporated. Connected to the pump to remove traces of dichloromethane. The syrup was used as such in the next step. TLC examination showed that the pentaacetate has been hydrolyzed to a polar anomeric hydroxy group (using 40% ethyl acetate and hexane mixture; staining was done with 10% sulfuric acid).


15

Preparation of 1-Trichloro acetamidoyl-2, 3,4,6-tetra-O-acetyl-glucopyranoside:

The syrup obtained above was dissolved in dichloromethane (350mL) and potassium carbonate (20g, powdered) was added. The mixture was stirred
20 magnetically and molecular sieves (50g) were added. The mixture was stirred for 10 minutes and trichloro acetonitrile (50g) was added. The mixture was stirred at room temperature for 14 hours. The mixture was filtered. Upon evaporation of solvents and excess trichloro acetonitrile, the desired chloroimidate was crystallized from by adding ether (150mL). The product
25 weighed 47g as a colorless white powder.

Proton NMR spectrum in CDCl₃ showed δ 8.7 (singlet, NH, 1-H); δ 5.95 (singlet, anomeric β -H; 1-H); δ 5.3-3.9 (multiplets, remaining 6-H glucosyl-H) 2.1-2.0 (overlapping singlets, 4 X 3-acetate-H)

Synthesis of R (-)-10-{\beta-D-2', 3', 4', 6'-tetra-O-acetyl glucopyranosyl-}, 11-hydroxyaporphine (apomorphine glucoside tetraacetate):



reaction 1

5

As shown in reaction 1 above, apomorphine (1.069g; 4 mMol) in dry dichloromethane (50mL) was stirred under argon and molecular sieves (15g) followed by glucosylating donor 1-trichloroacetamido-2,3,4,6-tetra-O-acetyl-
 10 glucopyranoside (2.452 g; 5 mMol) were added. The mixture was stirred under argon atmosphere at 20 to 25° C for 20 minutes. Boron trifluoride etherate (0.560 mL; 4.1 mMol) was added. The progress of the reaction was monitored by TLC using ethylacetate-hexane mixtures. The reaction was essentially complete within 45 minutes. The reaction was worked up by filtering off the molecular sieves and adding the organic portion to chilled saturated sodium
 15 bicarbonate solution (100 mL) and extracting the aqueous layer once with dichloromethane (100mL). The combined organic portion was dried over magnesium sulfate and evaporated. The product weighed 2.8 g.

Examination of the crude glucosylated product revealed that it is essentially a single product characterized by 4 doublets centered at δ 8.2, 7.1, 20 6.8 and 6.7 respectively (due to ortho coupling) and a multiplet at δ 7.2 due to the double ortho coupling for the five univalent aromatic protons. There were satellite peaks, which correspond to less than 10% of the major isomer. The above NMR pattern was identical to the starting apomorphine. The major 10-O-glucosylated-aporphine product was purified by SiO₂ column for
 25 obtaining authentic titled material. The flash SiO₂ column was eluted with

ether, chloroform and methanol mixtures. The tetra-O-acetyl glucopyronosylated apomorphine eluted first. The product was isolated as a white powder soluble in most of the organic solvents.

The proton NMR spectrum was recorded in CDCl₃. δ 7.9 (doublet, Ar-H, 1-H); δ 7.3-6.7 (multiplets, Ar-H, 4-H); δ 5-3.6 (multiplets, glucosyl-H, 7 H); δ 2.2-1.9 (overlapping singlets, acetyl-H and aliphatic 1-H, 13 H), δ 3.3-2.5 (multiplets, aliphatic-H and N-CH₃ singlet, 9-H).

Synthesis of R (-)-10-{\beta-D- glucopyranosyl-}, 11-hydroxyaporphine (apomorphine glucoside):

Apomorphine (1.069 g, 4 mMol) and trichloro acetimidoyl 2,3,4,6-tetra-O-acetyl glucopyranoside (2.452 g, 5 mMol) in dry dichloromethane (50mL) under argon atmosphere was stirred at 20 °C. Boron trifluoride etherate (0.56 mL) was added in small portions over 10 minutes and the mixture was allowed to stir for 45 minutes. The product mixture was poured into saturated sodium bicarbonate solution (100mL) and extracted with 2 X100 mL of dichloromethane. The combined organic layers were washed with water (50mL) and evaporated. The crude residue was dissolved in methanol (75 mL) and Dowex-550-OH resin (10g, without pretreatment) was added and the mixture refluxed for 2 hours. The resin was filtered off and washed once with methanol (20mL) and evaporated. The crude gum crystallized from ethyl acetate/methanol mixtures as pale pinkish- white crystals (1.3g)

The proton NMR spectrum was recorded in CD₃OD. δ 8.45 (doublet, 1-H, Ar-H); δ 7.25-7 (multiplet, Ar-H, 4-H); δ 5.3 (doublet, 7.2 Hz anomeric coupling, beta glucosidic linkage, 1-H); δ 3.9 to 3.0 (complex, aliphatic-H and sugar-H, 11 H); δ 2.75 (doublet, benzylic-H, 1 H); δ 2.6 (singlet, N-CH₃, 3-H) and δ 2.4 (triplet, benzylic-H, 1-H)

Mass spectrum: The molecular ion was obtained at 430.1 amu (theoretical value is 429.46 amu) in correspondence to the assigned structure.

1. A glycoside or orthoester glycoside derivative of apomorphine or analog thereof, or salt or ester thereof.

2. The derivative of claim 1, having the Formula (I):




or a salt or ester thereof;

wherein Apo is an apomorphine residue or analog thereof,

n is 1 or 2, and

each R₁ is independently a straight or branched chain glycosidic moiety
10 containing 1-20 glycosidic units, or R₁ is an orthoester glycoside moiety of the
Formula (II):




wherein A represents a glycofuranosyl or glycopyranosyl ring;

R₂ is hydrogen or alkyl;

15 R₃ is hydrogen or a straight or branched chain glycosidic moiety
containing 1-20 glycosidic units; or

when n is 2, both R₁ groups form a ketal or acetal having the
Formula (III):




20 wherein X is a straight or branched chain alkylene group;

R₄ and R₅ are independently hydrogen or an alkyl group; and


R₆ is a straight or branched chain glycosidic moiety containing 1-20 glycosidic
units or an orthoester glycoside as defined above.

3. The derivative of claim 1, having any one of formulas (IV), (V), (VI) or (VII):




5

IV'




V



10

VI




VII

or a salt, or ester thereof, wherein R_1 is defined above.

5 4. The derivative of claim 1, wherein said glycoside is a moiety containing 1-20 glycosidic units.

5. The derivative of claim 1, wherein said glycoside is a glycosidic orthoester having the Formula (II):

10



wherein A represents a glycofuranosyl or glycopyranosyl ring;

R_2 is hydrogen or alkyl;

R_3 is hydrogen or a straight or branched chain glycosidic moiety

15 containing 1-20 glycosidic units.

6. The derivative of claim 1, wherein said glycoside is a monoglycoside.

7. The derivative of claim 6, wherein said monoglycoside is a glucoside.

20

8. The derivative of claim 1, wherein said glycoside derivative of apomorphine is (-)-10- $\{\beta$ -D- glucopyranosyl- $\}$, 11-hydroxy aporphine.

9. A pharmaceutical composition comprising the derivative of claim 1 and a pharmaceutically acceptable carrier.
10. A method for the treatment or amelioration of sexual dysfunction in a human in need thereof, comprising administering to said human an effective amount of the derivative of claim 1.
11. The method of claim 10, wherein said dysfunction is erectile dysfunction.
12. The method of claim 10, wherein said dysfunction is female sexual dysfunction.
13. A method for the treatment or amelioration of Alzheimer's disease and other disorders involving memory loss and/or dementia; disorders of attention and focus; disorders of extrapyramidal motor function; mood and emotional disorders; comprising administering to an animal in need thereof, an effective amount of the compound of claim 1.
14. The method of any one of claims 10-13, wherein said derivative is administered as part of a pharmaceutical composition comprising a pharmaceutically acceptable carrier therefor.
15. The method of any one of claims 10-13, wherein said derivative is R (-)-10- $\{\beta$ -D- glucopyranosyl-}, 11-hydroxyaporphine.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US03/08448

A. CLASSIFICATION OF SUBJECT MATTER
 IPC(7) : A61K 31/7028, 31/485
 US CL : 514/284, 33; 546/77; 536/17.4
 According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED
 Minimum documentation searched (classification system followed by classification symbols)
 U.S. : 514/284, 33; 546/77; 526/17.4

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 5, 744,476 A (LOCKE et al) 28 April 1998 (28.04.1998), claims 11 and 12.	13, 14
Y	US 4,785,014 A (GOLDMAN-RAKIC et al) 15 November (15.11.1988), column 2, line 60 to column 3, line 11	13, 14
X	US 6,506,765 B2 (GUPTA et al) 14 January 2003 (14.01.2003), column 2, lines 47-67.	1-4, 6, 9-12, 14
---		-----
Y		15

Further documents are listed in the continuation of Box C. See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"B" earlier application or patent published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search: 20 June 2003 (20.06.2003)
 Date of mailing of the international search report: 24 JUL 2003

Name and mailing address of the ISA/US: Mail Stop PCT, Attn: ISA/US, Commissioner for Patents, P.O. Box 1450, Alexandria, Virginia 22313-1450
 Facsimile No. (703)305-3230
 Authorized officer: Michael C. Henry
 Telephone No. (703) 308-1235